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Abstract 
Background: Dexamethasone has analgesic 
and antiemetic actions that have been 
documented in the literature. Therefore, we 
performed a systematic review and meta-
analysis to investigate its overall effectiveness in 
reducing a variety of negative outcomes after 
cesarean section. 
Objectives: To investigate the efficacy and 
safety of dexamethasone for reducing pain 
associated with cesarean section, nausea, 
vomiting, pruritus, postoperative need for 
analgesia, postoperative antiemetic requests 
and headache. 
Methods: We searched PubMed, Cochrane 
CENTRAL, SCOPUS, and Web of Science for 
relevant clinical trials. We then performed a 
systematic review and meta-analysis, including 
only randomized, placebo-controlled clinical 
trials. Our main population target was women 
undergoing elective cesarean delivery. The 
intervention under consideration was 
dexamethasone administered both by 
intravenous (IV) or subcutaneous (SC) over a 
variety of doses. The comparator was a placebo. 
Our main outcomes included: (1) perceptions as 
indicated by pain scores, (2) occurrence of 
nausea and (3) occurrence of vomiting. 
Secondary outcomes included: (4) occurrence of 
pruritus, (5) need for postoperative analgesia, 
(6) need for postoperative antiemetic drugs and 
(7) occurrence of headache. We assessed the 
quality of included studies using the risk of bias 
tool described in Cochrane's handbook for 
systematic reviews of interventions. 
Results: We found that dexamethasone 
seemed to significantly reduce scores for pain at 
rest (p<0.001), as well as occurrence of nausea 
(p<0.001) and vomiting (p<0.001). The drug also 
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showed significant reduction of negative 
symptoms in other secondary outcomes, 
including need for postoperative analgesia 
(p<0.001) and postoperative antiemetic drugs 
(p<0.001). However, the drug showed no 
significant effect in reducing headache and 
pruritus or in improving pain at movement 
scores. 
Conclusion: Dexamethasone appears to 
decrease perception of pain at rest and protects 
against nausea and vomiting. However, it does 
not seem effective against headaches or 
pruritus. 
1Faculty of Medicine, Fayoum University, 
Fayoum, Egypt. 
2Department of Obstetrics and Gynecology, 
Cairo University, Cairo, Egypt 
3Department of Obstetrics and Gynecology, 
Assiut University, Assiut, Egypt. 
Introduction 
Cesarean delivery is an intensive 
procedure that demands a longer 
healing process than vaginal delivery. 
Nevertheless, it is one of the most 
prevalent surgical procedures in 
obstetrics and gynecology. As such, it 
has been performed with increasing 
frequency in recent years,1 and has 
played a prominent role in decreasing 
perinatal morbidity and mortality. 
Cesarean section (CS) may be 
medically mandatory for various 
reasons, including when labor is not 
progressing, in cases that have of a 
history of multiple gestations, when the 
fetus experiences an emergency or 
severe health concern, if the mother has 
a contagious virus or when there are 
complicating conditions, such as 
diabetes or hypertension.2,3 During this 
procedure, patient discomfort is 
addressed with general anesthesia, and 
epidural or spinal blocks. However, 
patients may also experience a number 
of postoperative complications, including 
pain, vomiting, pruritus, headache and 
nausea.4  
Dexamethasone is a glucocorticoid, 
known for its potent anti-inflammatory 
effect, which can be used as a 
postoperative pain control agent in 
many surgeries, including obstetrical 
and gynecological procedures.5-7 In 
addition, it can be used as an antiemetic 
in various surgeries.8,9 Although the 
mechanism of action of glucocorticoids 
is not fully understood, suggested 
theories include inhibiting the production 
of inflammatory mediators such as 
prostaglandin and bradykinin, 
preventing reduction of the "pain 
threshold" that occurs during surgeries, 
and decreasing tissue swelling through 
its anti-inflammatory effects and thereby 
inhibiting nerve compression by 
inflammatory tissue.10-12  
Multiple studies confirm the analgesic 
and antiemetic effects of 
dexamethasone in various surgeries 
such as laparoscopic hysterectomy and 
CS.13,14 The literature is full of clinical 
trials investigating the effect of 
dexamethasone on pain, nausea and 
vomiting. However, only a few of the 
systematic review and meta-analysis 
studies have investigated only the 
postoperative efficacy of 
dexamethasone, as Allen et al. did when 
they investigated its effect after both 
hysterectomy and cesarean section 
operations.15 In addition, we intended to 
investigate the postoperative effects of 
dexamethasone when it is administrated 
at different doses (2.5, 8, 10, or 16 mg) 
and by different routes (intravenous (IV) 
or subcutaneous (SC)). However, the 
existing heterogeneity between studies 
and the low number of studies that 
investigate some doses (such as 2.5 or 
16 mg) acted as limitations on this study 
and suggest areas for future research. 
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As a result, we aim to investigate the 
impact of any dose of dexamethasone 
administered either by IV or SC routes 
on perception of pain and the incidence 
of nausea and vomiting. 
Materials and Methods  
In this analysis, we followed PRISMA 
guidelines.16 We performed a systematic 
search for published, randomized 
clinical trials comparing dexamethasone 
(given in any dose, by any route of 
administration except by transverse 
abdominal plane block or intrathecal 
route) with placebo for decreasing post-
CS pain. Efficacy was determined using 
pain scores -- as estimated using a 
Visual Analogue Scale (VAS) or 
Numerical Rating Scale (NRS) -- as well 
as occurrences of nausea and vomiting 
to determine primary outcomes in 
patients scheduled for elective CS at 
term. Our secondary outcomes included 
relative occurrence of headache, 
pruritus, postoperative rescue analgesia 
and postoperative rescue antiemetic. 
Searching and Eligibility Criteria 
To find data for this study, we searched 
PubMed, Web of Science, the Cochrane 
Central Register of Controlled Trials, 
and Scopus. The search strategy used 
was ((((((((((((((((Dexamethasone) OR 
Dexamethasone (MeSH Terms)) OR 
Methylfluorprednisolone) OR 
Hexadecadrol) OR Decameth) OR 
Decaspray) OR Dexasone) OR Dexpak) 
OR Maxidex) OR Millicorten) OR 
Oradexon) OR Decaject) OR Decaject-
L.A) OR Decaject L.A) OR Hexadrol)) 
AND ((((((((((((Cesarean) OR Cesarean 
Section) OR Cesarean Section(MeSH 
Terms)) OR Caesarean Sections) OR 
Abdominal Delivery) OR C-Section) OR 
C-Sections ) OR Abdominal Deliveries) 
without language restriction, up to 
August, 2020. 
Eligibility criteria were as follows: (1) 
limited to women undergoing CS, (2) 
intervention: dexamethasone IV or SC, 
(3) comparator: placebo, (4) outcome 
data: pain, nausea and vomiting, and (5) 
study design: randomized clinical trials. 
We excluded animal trials, conference 
abstracts and irrelevant articles. 
Data extraction 
We extracted the following data from 
each of the prior studies that met the 
inclusion criteria: (i) anesthetic drug and 
technique; (ii) dose, timing and route of 
administration of dexamethasone; (iii) 
basic characteristics of study 
participants such as age, weight, body 
mass index (BMI), weeks of gestation, 
duration of operation, drugs used for 
relieving pain or gastrointestinal (GIT) 
symptoms, as well as the scales used to 
assess pain scores; (iv) outcome 
measures including pain score, and 
incidences of nausea, vomiting, 
headache, pruritus, postoperative 
rescue analgesia, postoperative rescue 
antiemetic and retching. 
Risk of bias for included studies 
We assessed the risk of bias (ROB) in 
each of the studies according to the 
Cochrane's risk of bias tool.17 We 
imported articles using EndNote (X8.2), 
removing duplicates. Remaining studies 
were then screened according to 
eligibility criteria. We extracted data and 
performed an analysis using 
RevMansoftware.  
Data Synthesis and Analysis 
For our study, we performed an analysis 
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of the data our selected studies reported 
during the first 24 hours postoperatively. 
Pain outcomes were reported in a 
variety of ways: some studies reported 
pain at movement, others reported at 
rest pain, and some studies did not 
report if pain occurred during movement 
or at rest but were assumed to have 
been taken at rest, as in Allen et al.15 
Extracted dichotomous data were 
analyzed using relative risks (RRs) with 
95% confidence intervals (CIs). A lack of 
statistical significance across groups 
was assumed if the value of CI at 95% 
was 1. Meanwhile, in continuous data, 
the likelihood of statistical significance 
was represented using means and 
standard deviations, while standardized 
mean difference (SMD) with 95% CI 
were used for summarization. 
A value of 1 at 95% CI was chosen to 
indicate a lack of statistical significance. 
Formulas recommended by Hozo et al.18 
were used to determine mean and 
standard deviation from data expressed 
as median and range in the studies 
evaluated in this research. In most 
cases, a fixed text model was used as a 
default. However, when outcomes were 
heterogeneous, a random-effects model 
was used. Significant heterogeneity was 
defined as P (value for heterogeneity) < 
0.1 and as I2> 50%. In a search for 
causal factors, heterogeneous 
outcomes were solved first by 
attempting the leave-one-out method, 
then by performing subgroup analysis. 
Forest plots were used as graphical 
representations of outcomes for both 
groups. Funnel plots, as described by 
Egger et al., were used to assess any 
publication bias.19 When outcomes were 
not consistently reported, and 
quantitative analysis was inappropriate, 
they were reviewed qualitatively. 
Results 
Results of the literature search 
Our literature search found 1344 
published articles. After removing 346 
duplicates, the remained 998 articles 
were used for title and abstract 
screening. During this process, we 
excluded 934 additional studies, so that 
64 studies remained for full-text 
screening. After the full-text screening, 
40 articles were excluded as they did 
not match the inclusion criteria. As a 
result, only 24 articles were included in 
our study. (Figure 1) The included 
studies had a combined total population 
of 2840 patients, 1560 in 
dexamethasone groups and 1280 in 
placebo groups. Some studies used 
dexamethasone 8 mg by IV 
route,11,13,20-35  while others used 16 mg 
dexamethasone by both SC and IV 
routes as separate groups.36,37 One 
study reported three dexamethasone 
groups using various doses (2.5 mg, 5 
mg, and 10 mg) by IV route.38 Another 
study used 2 mg of dexamethasone,39 
while a third used 0.6 mg/kg of 
dexamethasone (10 mL).40 Some 
studies introduced the intervention pre-
operatively, 11,13,23,27,28,30,34 while other 
studies introduced the intervention intra-
operatively. 21,22,24-26,29,31-33,35,37,38,41 The 
remaining studies introduced the 
intervention post-operatively. 20,36,39 One 
study did not report the time of 
administration.40 (Supplemental Table 1) 
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Figure 1. PRISMA flow diagram for searching results and screening process 
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Figure 2. Risk of bias summary of included studies 
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Results of risk of bias assessment 
Assessment of risk of bias in the 
included studies is outlined in Figure 2. 
With regard to random sequence 
generation, all studies were at low risk 
for bias except for seven studies rated 
at unclear bias as they did not report 
sufficient information. 24,27,28,30,32,35,38 
In most of the studies included in this 
research, the allocation concealment 
process was clearly stated.20,29,31-33,40,41 
However, seventeen of the randomized, 
controlled studies (RCTs) used had 
unclear risk as authors did not indicate if 
they performed allocation 
concealment.11,13,21-28,30,34-39 
All studies showed low-risk performance 
bias with regard blinding of participants 
and personnel. While almost all studies 
demonstrated blinding of outcome 
assessors, four studies did not report 
enough information to determine the 
extent of blinding.22,23,33,41 Furthermore, 
three trials had a high risk of bias as 
they were single-blinded.29, 36, 40 
Almost all studies showed low risk for 
bias due to incomplete outcome data, 
except four trials did not explicitly report 
on missing data points.22,28,39,40 
 
Figure 3. Publication bias in pain at rest outcome 
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The majority of studies included in this 
research showed low risk for bias due to 
selective reporting strategies. Only nine 
studies were considered high risk: five 
studies reported data ineligible for meta-
analysis11,22,34,38,39 and four studies did 
not report important primary 
outcomes.21,23,29,31 Ten studies were 
free from other bias.21,23,29,30,33,34,36, 
38,39,41 Eight studies had unclear risk; two 
did not evaluate P-values for rescue 
analgesic outcomes,20, 25 and six studies 
did not publish protocols.11,13,22,24,26,32 
The rest of the studies showed high risk 
for adjusted small sample size,27,28,31, 
32,40 and for ending before completing 
enrollment of their subjects.35  
More than ten studies reported three 
outcomes; therefore, publication bias 
estimation was possible. A Begg's 
funnel plot showed no publication bias 
regarding vomiting and pain-at-rest 
outcomes (Figures 3, 4), as these 
studies were scattered symmetrically. 
However, outcomes for nausea were 
significant for publication bias. (Figure 5) 
 
 
Figure 4. Publication bias in vomiting outcome 
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Figure 5. Publication bias in nausea outcome 
 
Synthesis of Results 
Findings for the various adverse 
outcomes of CS were evaluated for 
homogeneity as opposed to 
heterogeneity of findings across 
included studies, dosages and methods 
of administration (IV v. SC). Each 
potential adverse outcome varied with 
respect to these features. In some 
instances, there was little difference 
between dexamethasone groups and 
those given placebo. In other cases, the 
frequency with which dexamethasone 
relieved adverse symptoms varied 
across dosages and method of 
administration (IV v. SC). Findings that 
favored dexamethasone groups 
indicated that the majority of original 
study findings showed reduction or 
elimination of negative symptoms or 
medication needs. 
Pain scores  
Thirteen studies reported outcomes 
based on pain scores.11,13,20-22,27,31,32,34-
38 Some studies reported pain scores at 
movement while others reported scores 
at rest. Unique to the four studies that 
reported pain at movement,11,13,31,35 was 
a lone study that reported data that was 
not eligible for analysis. In this case, 
Cardoso et al., reported a significant 
decrease in at-movement pain at 24 
hours post-procedure in the 
dexamethasone group of 5 (14%) as 
compared with the placebo group of 15 
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(43%, P =0.01).13 Of the three remaining 
studies in our meta-analysis,11,31,35 pain 
scores were not significantly decreased 
in dexamethasone groups (SMD = -
0.54, 95% CI (-1.39, 0.31), P = 0.22). A 
random-effects model was used to 
resolve the heterogeneity (P = 0.001, I² 
= 85%) in these findings. (Figure 6A) 
Because heterogeneity was solved by 
the leave-one-out method, data from Wu 
et al. was not included in findings for 
pain.11 As a result, the standard mean 
deviation (SMD) became -0.10, 95% CI 
(-0.50, 0.29), P = 0.61. With this change, 
the results became homogeneous (P = 
0.59, I² = 0%). (Figure 6B) 
 
Figure 6. Effect of dexamethasone on relieving movement pain 
 Figure 6A. Effect of dexamethasone on relieving movement pain before removing Wu et al.  
 Figure 6B. Effect of dexamethasone on relieving movement pain after removing Wu et al. to  
  solve the heterogeneity 
 
The remaining studies reported findings 
for pain at rest.11,13,20-22,27,31,32,34-38 Of 
these, three studies were not eligible for 
analysis. Cardoso et al. reported no 
difference in the incidence of pain at 24 
hours between participants receiving 8 
mg IV dexamethasone (n = 5, 14%) and 
placebo (n = 10, 29%),13 while Shalu et 
al. reported a significant decrease in 
pain scores at 24 hours in a group given 
IV dexamethasone (mean = 5) as 
compared with a group given IV saline 
(mean = 6, p <0.001).22 In addition, 
Selzer et al. found no significant 
difference in pain score between two 
groups at 48 hours.34 With these 
exclusions, ten studies remained for 
analysis.11,20,21,27,31,32,35-38 Overall, the 
total mean standard deviation for pain 
scores across all studies for participants 
receiving dexamethasone was 
significant (SMD = -0.78, 95% CI (-1.23, 
-0.32), P = 0.0009). (Figure 7A) Pooled 
results were heterogeneous (P = 
0.00001, I² = 91%). This heterogeneity 
was assumed to be the result of random 
effects but could not be resolved by 
either by leave-one-out or subgroup 
analysis. Similarly, subgroups based on 
dose, route of administration, country of 
residence, anesthetics used, or 
administration time did not solve 
Proceedings in Obstetrics and Gynecology, 2021;10(2):2 
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heterogeneity. 
 
Figure 7. Effect of dexamethasone on relieving rest pain 
 Figure 7A. Overall analysis of all doses of dexamethasone on relieving rest pain 
 Figure 7B. Analysis result of 8 mg IV dexamethasone on relieving rest pain 
 Figure 7C. Analysis result of 16 mg IV dexamethasone on relieving rest pain 
 Figure 7D. Analysis result of 16 mg SC dexamethasone on relieving rest pain 
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In general, differences in pain scores for 
the dexamethasone groups did not vary 
widely from those for placebo. However, 
there was variation based on dosage 
given. For example, pain scores were 
significantly decreased for 8mg of IV 
dexamethasone as compared with 
placebo (SMD = -1.12, 95% CI (-1.68, -
0.55), P = 0.0001).11,20,21,27,31,32,35 
(Figure 7B) However, the SMD was not 
significantly different with 16 mg of IV or 
SC dexamethasone, (SMD = 0.16, 95% 
CI (-1.04, 1.36), P = 0.79 and SMD = -
1.48, 95% CI (-4.03, 1.08), P = 0.26) 
respectively.36,37 (Figures 7C, 7D) 
Similarly, there was no significant 
difference between 2.5, 5 or 10 mg of IV 
dexamethasone and placebo.38  
Nausea 
In this research, 17 out of 24 studies 
reported outcomes for the occurrence of 
nausea. 11,13,20,24,25,27,28,30-36,38,40,41 Ituk et 
al. did not report data eligible for meta-
analysis. They found no significant 
difference between dexamethasone and 
placebo groups with regard to nausea 
severity scores across the following 
periods: (1) from 6 to 12 hours, p = 0.82, 
(2) from 12 to 24 hours, p = 0.67, or (3) 
from 0 to 6 hours, p = 0.10.31 Selzer et 
al. also found no significant difference 
between the two groups at 48 hours.34  
Findings for the remaining 15 studies 
indicated that the relative risk (RR) of 
the occurrence or severity of nausea 
was significantly more likely in the 
dexamethasone group (RR = 0.57, 95% 
CI (0.47, 0.69), P < 0.00001). Pooled 
results were homogeneous (P = 0.14, I² 
= 27%). (Figure 8A) In studies in which 
8 mg IV dexamethasone was 
administered, the RR most significantly 
favored the dexamethasone group (RR 
= 0.55, 95%CI (0.42, 0.72), P < 0.001), 
indicating decreased occurrence or 
severity of nausea. (Figure 8B) 
The incidence of nausea was 
significantly lower in groups that 
received 2.5, 5 and 10 mg of IV 
dexamethasone as compared with those 
who received placebo.38 Nausea 
incidence significantly decreased with 
a16 mg IV dose, and there were no 
significant differences between groups 
that received 16 mg SC dexamethasone 
and those who were given placebo.36 
Relative risk of nausea was also not 
significant among those given 0.6 
mg/Kg of IV dexamethasone.40  
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Figure 8. Effect of dexamethasone on decreasing nausea incidence 
 Figure 8A. Overall analysis of all doses of dexamethasone on decreasing nausea  
 Figure 8B. Analysis result of 8 mg IV dexamethasone on decreasing nausea  
 
Vomiting 
Seventeen studies used in this research 
reported outcomes for occurrence of 
vomiting.11,13,20,21,24-28,30-35,38,39 Four 
studies did not provide sufficient data for 
analysis. Sharkahi et al. reported a 
significant difference in vomiting severity 
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upon recovery room entrance between 
the dexamethasone and placebo 
groups, P < 0.001.21 However, there 
were no significant reported differences 
during the remaining period of the 
Sharkahi study.21 Yousefshafhi et al. 
reported no significant difference in the 
incidence of nausea and vomiting 
between the two groups, where n = 99 
(54.4%) in the dexamethasone group 
and n = 92 (51.7%) in the placebo group 
and P = 0.673.26 Modir et al. reported no 
significant difference in intraoperative 
and postoperative vomiting VAS scores 
between dexamethasone and placebo 
groups.39 Selzer et al. reported that the 
incidence of postoperative nausea and 
vomiting at 48 hours was higher in the 
dexamethasone group, where n = 29 
(52.7%) than the incidence in the 
placebo group, where n = 24 (45.3%).34 
However, this was not a significant 
difference. For the 13 remaining 
studies,11,13,20,24,25,27,28,30-33,35,38 overall 
relative risk significantly favored the use 
of dexamethasone (RR =0.57, 95% CI 
(0.44, 0.73), P<0.001). In addition, 
pooled results were homogeneous (P= 
0.32, I² =12%). (Figure 9A) The RR in 
studies using 8 mg IV dexamethasone 
significantly favored the use of 
dexamethasone for the reduction of 
vomiting (RR = 0.61, 95%CI (0.46, 
0.81), P < 0.001). (Figure 9B) 
Meanwhile, the incidence of nausea and 
vomiting was significantly lower for 
groups given 2.5, 5 and 10 mg of IV 
dexamethasone compared as with those 
given placebo.38  
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Figure 9. Effect of dexamethasone on decreasing vomiting 
 Figure 9A. Overall analysis of all doses of dexamethasone on decreasing vomiting 
 Figure 9B. Analysis result of 8 mg IV dexamethasone on decreasing vomiting 
 
Headache  
In this research, five studies reported 
outcomes for the incidence of 
headaches.23,26,29,40,41 The total RR did 
not show a significant difference 
between either of the two groups (RR = 
0.92, 95% CI (0.37, 2.31), P = 0.86). 
Pooled results were heterogeneous (P = 
0.0008, I² = 79%) (Figure10A). Neither 
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leave-one-out or subgroup analysis 
according to dose, administration route, 
the drug used for anesthesia or country 
of residence of study participants could 
be used to resolve these differences 
across these studies. The RR was not 
significantly different between 8 mg and 
0.6 mg doses of IV dexamethasone (RR 




Figure 10. Effect of dexamethasone on decreasing headache  
 Figure 10A. Overall analysis of all doses of dexamethasone on decreasing headache 
 Figure 10B. Analysis result of 8 mg IV dexamethasone on decreasing headache 
 
Pruritus 
Four studies reported outcomes for the 
occurrence of pruritus.11,20,25,27 The total 
RR of pruritus incidence did not favor 
any group (RR = 0.96, 95% CI (0.80, 
1.14), P = 0.61). Pooled results were 
homogeneous (P = 0.95, I² = 0%). 
(Figure 11) 
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Figure 11. Effect of dexamethasone on decreasing pruritus 
Postoperative rescue analgesia 
Six studies reported outcomes involving 
a need for post-operative rescue 
analgesic.11,20,25,34,36,38 However, Selzer 
et al. found no significant difference in 
the amount of analgesic drugs used in 
48 hours between the two groups, and 
therefore it was not eligible for use in 
our meta-analysis.34 The total RR of the 
remaining five studies favored 
dexamethasone significantly (RR = 0.70, 
95% CI (0.59, 0.84), P < 
0.001).11,20,25,34,36,38 (Figure 12A) Pooled 
results were homogeneous (P = 0.83, I² 
= 0%). The RR was not significant for 8 
mg of IV dexamethasone (RR = 0.78, 
95% CI (0.55, 1.11), p = 0.16).9,18,23 
(Figure 12B). The incidence of requests 
for analgesic drugs was different but not 
significant for 2.5, 5 10 and 16 mg 
doses of IV dexamethasone as 
compared with placebo.38 It was also not 
significantly different from the IV 16 mg 
dose. However, the need for analgesic 
drugs was significantly reduced for a16 
mg SC dose.36  
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Figure 12. Effect of dexamethasone on decreasing analgesic drug using 
 Figure 12A Overall analysis of all doses of dexamethasone on decreasing analgesic drug  
 using. 
 Figure 12B.: Analysis result of 8 mg IV dexamethasone on decreasing analgesic drug using. 
 
Postoperative rescue antiemetic 
There were ten studies that reported 
outcomes where post-operative rescue 
antiemetics were needed.11,20,24-
26,30,31,34,35,38 Selzer et al. reported that 
the outcome during the first 48 hours did 
not favor any group and, hence, was not 
eligible for meta-analysis.34 However, 
the rest of the studies reported the need 
for antiemetics during 24 hours 
postoperative, and the total RR 
significantly favored findings for groups 
receiving dexamethasone (RR=0.65, 
95% CI (0.47, 0.90), P=0.01). Pooled 
results were heterogeneous (P=0.0005, 
I2=68%).11,20,24-26,30,31,35,38 (Figure 13A) 
Heterogeneity could not  be resolved by 
the leave-one-out method or subgroup 
analysis based on dose, route of 
administration, the drug used for 
anesthesia, or country where the RTC 
was conducted. The RR for 8 mg IV was 
not significant (RR=0.76, 95% CI (0.55, 
1.06), P = 0.11)11,20,24-26,30,31,35 (Figure 
13B) The incidence of requests for 
antiemetic drug significantly decreased 
with 5 and 10 mg IV doses of 
dexamethasone, while there was no 
significant difference between 2.5 mg IV 
dexamethasone and placebo.38 
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Figure 13. Effect of dexamethasone on decreasing antiemetic drug using 
 Figure 13A. Overall analysis of all doses of dexamethasone on decreasing antiemetic drug  
 using. 
 Figure 13B. Analysis result of 8 mg IV dexamethasone on decreasing antiemetic drug using.  
 
Discussion 
The present meta-analysis found that 
dexamethasone appears to significantly 
reduce pain associated with CS. 
Moreover, dexamethasone 
administration leads to a significant 
decrease in nausea and vomiting in 
patients. Outcomes for the incidence of 
headache and pruritus were equal in 
both arms. Requests for both 
postoperative rescue antiemetic and 
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rescue analgesic, as well as the 
occurrence of retching were significantly 
lower in the dexamethasone arm. 
Our findings are similar to those found in 
the current literature for other types of 
surgeries. For example, in a recent 
meta-analysis, dexamethasone was 
found to decrease pain after spinal 
anesthesia.42 In addition, IV 
administration of dexamethasone was 
shown to reduce morphine consumption 
in the first 24 postoperative hours.42 
Another study found that, because 
dexamethasone has been found to pair 
well with many adjunctive interventions 
to decrease pain, the combination of 
dexamethasone and mepivacaine led to 
significantly longer duration of 
analgesia.43 Yet another study showed 
increased analgesia time for 
bupivacaine administration with 
dexamethasone as an adjunctive 
therapy.44 
A large, systematic review and meta-
analysis by Allen et al. concluded that 
dexamethasone administration exerts 
significant antiemetic properties.15 In 
addition, this study shows that 
dexamethasone helped reduce 
postoperative analgesia usage by 
patients. However, the same study 
reported that dexamethasone was not 
effective for preventing neuraxial 
morphine-induced pruritus.15 The use of 
dexamethasone is widespread in 
different surgical interventions. In 
addition, a study found that the drug 
helps in prophylaxis against nausea and 
vomiting following thyroidectomy.45 
Another study found that nausea and 
vomiting were significantly lower in 
patients administered dexamethasone 
before cholecystectomy.46 
The results of previous trials, reviews 
and meta-analyses support our study. 
Dexamethasone has been widely used 
for reducing postoperative pain, nausea 
and vomiting. This resulted in a large 
number of trials that could be included in 
our review. The resulting heterogeneity 
in our analysis could be used to call into 
question the accuracy of some of our 
results. However, the fact that we used 
27 multi-national trials implies a certain 
level of anticipated heterogeneity, given 
the diversity in each trial's methodology. 
Nor did we find significant homogeneity 
when subgroups were re-evaluated 
based on dose or route of 
administration, or by country in which 
the RCT was performed. We can say, 
however, that the findings in our study 
were consistent with those found across 
available literature. 
The main strength of our meta-analysis 
is that it includes a large number of fair-
sized clinical trials. We had 27 studies, 
with a total of 2966 participants. As far 
as we know, we included all previously 
published, relevant clinical trials, as our 
data bases were searched twice to 
make sure that no additional, supporting 
information was missed. Another strong 
point in our analysis is that there is low 
total risk of bias, as most of the included 
studies were adequately designed, 
which provided more precise, stronger 
evidence. 
The main limitation of our study is the 
presence of heterogeneity. For example, 
we were unable to account for the cause 
of large, heterogeneous results for 
outcomes involving pain. Another 
limitation is the presence of publication 
bias in two of our outcomes. This 
indicates that our results may have been 
affected by heterogeneity or missing 
data, which was another limitation that 
we encountered. Although we reported 
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nearly all outcomes, some studies 
reported outcomes in a way that was 
inconsistent with the other data used in 
this research. For example, pain scores 
were dichotomized in four studies. This 
inconsistency was also noted in other 
primary outcomes, which may have led 
to the masking of correct results. 
In conclusion, dexamethasone 
administration appears to be effective in 
reducing pain associated with CS. In 
addition, its use seems to lead to lower 
incidence of nausea, vomiting, retching, 
postoperative analgesia requests and 
postoperative antiemetic needs. 
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